Stay updated with breaking news from Merck Sharp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") and Seagen Inc. (Nasdaq: SGEN) today announced that on November...
/PRNewswire/ -- The "KEYTRUDA Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This report provides...
Genital Warts (Condyloma Acuminatum) MarketThe genital warts (condyloma acuminatum) market is predicted to grow from its current value of US$ 1.87 billion in 2023 to US$ 3 billion by 2033, with a CAGR of 4.84%. Due to the anticipated introduction of novel medications, the dynamics of the genital warts market are ant...
Researchers have reported “encouraging” results with neoadjuvant pembrolizumab and anthracycline-free chemotherapy in patients with TNBC. Researchers have reported “encouraging” results with neoadjuvant pembrolizumab and anthracycline-free chemotherapy in patients with TNBC.
NextCure (NASDAQ:NXTC – Get Free Report) and NGM Biopharmaceuticals (NASDAQ:NGM – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings. Insider & Institutional Ownership 47.8% of NextCure shares […]